Valsartan to Prevent Left Ventricle Remodeling in Pacemaker Patients
Status:
Unknown status
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
Dual chamber pacing is known to induce left ventricle remodeling and may eventually lead to
heart failure. The investigators aim to test hypothesis that valsartan started immediately
after dual chamber pacemaker implantation will prevent left ventricle remodeling in twelve
months long follow up in comparison with placebo. Echocardiographic assessment of left
ventricle remodeling will be correlated with plasma activity of matrix metalloproteinases and
their tissue inhibitors, indices of functional capacity such as plasma level of NTproBNP and
distance in meters during six minute walking test.